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Abstract
Many studies have investigated APOE-related differences in cerebral structure, blood flow,
metabolism, and activation in an attempt to detect early brain changes in subjects at risk for
Alzheimer's disease (AD). Structural magnetic resonance imaging studies have produced
conflicting results, with some failing to detect APOE-related differences and others suggesting
that ε4 carriers have more pronounced atrophy, particularly at medial temporal structures. All
functional imaging studies done during rest in middle-aged and elderly subjects have found
decreased cerebral metabolism for ε4 carriers (mostly in areas that usually are affected by AD),
and some have reported faster cerebral metabolic reductions over time. Areas with decreased
resting cerebral perfusion and metabolism, in addition to other areas with increased perfusion,
have been reported in young ε4 carriers. Imaging studies done during the performance of various
cognitive tasks in middle-aged and elderly subjects, and a single study in young subjects, have
produced mixed results with regionally nonspecific increased, decreased, or nondifferential
APOE-related activations depending on the cognitive task used. APOE-related findings in imaging
studies of nondemented subjects may be the result of incipient AD pathologic changes or of
genetic heterogeneity in brain structure and function.
Introduction
Multiple epidemiologic studies have established that the APOE is the most important
susceptibility gene for sporadic Alzheimer's disease (AD) [1–3]. The ε4 allele has a dose-
related effect on risk for sporadic AD, whereas the ε2 allele seems to confer protection [4].
Although it is conceivable that the clinical heterogeneity observed in AD could derive from
APOE-related underlying genetic variability [5], the relation of APOE to different AD
clinical and phenotypic subtypes after the onset of disease is less clear. Many studies have
attempted to investigate the effects of the APOE genotype on brain structure and function
before [6–10,11•,12–16,17•,18,19••,20•,21–24,25•,26,27•,28,29••] or after [6,30–33] clinical
AD onset. However, treatment for AD may be more effective if applied early in the disease
process (if possible, before clinical disease is manifested). Therefore, it is very important
that early AD changes in subjects at risk for AD, such as ε4 carriers, be identified early. In
this article, we review and discuss imaging studies done in nondemented subjects, and
investigate associations between the APOE genotype and structural and functional cerebral
changes.
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Middle-aged and elderly subjects
In a magnetic resonance imaging (MRI) study of 125 cognitively normal elderly control
subjects, MRI-assessed hippocampal volumes did not differ on the basis of APOE genotype
[6]. Another MRI study included 137 subjects, comprising a mixture of participants with
normal cognition, memory difficulties, and few subjects with mild dementia (n = 16) [7].
Entorhinal cortex and hippocampus volumes did not differ in relation to APOE genotype.
According to an MRI study of 26 nondemented subjects, there were no APOE-related
differences in hippocampal volumes [8]. The subjects had repeated MRIs approximately 2.5
years later. ε4 carriers showed significantly faster hippocampal volume loss (2.86% per
year), as compared with non-ε4 carriers (0.85% per year). There were no significant
differences between ε4 homozygotes and ε4 heterozygotes. Rates of change of total brain
volume did not differ by APOE genotype.
In a study of 113 cognitively normal, late middle-aged adults, the presence of the ε4 allele
had a dose-related reduction (ie, more prominent reduction for ε4 homozygotes, as
compared with ε4 heterozygotes, and for ε4 heterozygotes as compared with non-ε4 carriers)
of MRI gray matter in regions known to be affected early in AD, including the posterior
cingulate, bilateral parahippocampal/lingual gyri, and left parietal and anterior cingulate/
medial frontal areas [9].
In an MRI study of 32 healthy elderly subjects (16 with age-associated memory decline, and
16 with normal memory), ε4 homozygotes had significantly smaller right (as compared to
left) hippocampus [10]. This pattern of hippocampal asymmetry was opposite to that
observed in non-ε4 carriers (ie, larger right hippocampus). These results were interpreted as
concordant with studies after the onset of AD, indicating a more severe volume loss in the
right hippocampus for ε4 homozygotes [30].
In a large MRI study of 1077 nondemented subjects in their early 70s, ε4 carriers had
significantly more hippocampal and amygdala atrophy than ε3/ε3 subjects on the left and
right sides [11•]. Hippocampal and amygdalar volumes decreased with increasing ε4 doses.
There was no difference between ε2 carriers and ε3/ε3 subjects. Measures of global (cortical
and subcortical) brain atrophy did not differ by APOE genotype. The results were similar
when subjects with low memory performance were excluded.
Another MRI study included 193 subjects with mild cognitive impairment (MCI) as
compared with non-ε4 carriers. Women with one or two ε4 alleles were found to have
significantly reduced hippocampal volume, whereas men only showed a significant
reduction in hippocampal volume when carrying two ε4 alleles [12]. When controlling for
memory performance on delayed word recall, the APOE effect on hippocampal volumes
was attenuated in men, but remained significant in women. The authors concluded that the
APOE genotype status seems to have a greater deleterious effect on gross hippocampal
pathology in women than in men.
In an MRI study of 21 cognitively normal elderly twin subjects, six ε4 carriers and 14
noncarriers were indistinguishable based on neuropsychologic measures [13]. Nevertheless,
mean right and left hippocampal volumes were significantly smaller for ε4 carriers.
Young subjects
In a study of 70 healthy pediatric subjects who received brain MRI at age 10 years, there
was no relation between APOE status and hippocampal volume [34]. For 50 of these
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subjects who received a second MRI 2 years later, there was no association between APOE
status and longitudinal changes in hippocampal volume [34].
Functional Imaging During Rest
Middle-aged and elderly subjects
In a study of nondemented middle-aged subjects with memory complaints who had at least
two relatives with AD, 12 participants with ε4 and 19 participants without the ε4 allele were
scanned with fluorodeoxyglucose positron-emission tomography (FDG-PET) [14]. Subjects
with the ε4 allele did not differ from those without the ε4 allele in mean age or in
neuropsychologic performance. Parietal metabolism was significantly lower, and left-right
parietal asymmetry was significantly higher in subjects with the ε4 allele, as compared with
those without the ε4 allele.
The same investigators reported similar results from a FDG-PET study that included 27 ε4
carriers and 27 ε4 noncarriers who were elderly, dementia-free, and who had memory
complaints and/or family history of dementia [15]. In region of interest (ROI) analyses,
compared with ε4 noncarriers, ε4 carriers had significantly lower metabolism in bilateral
inferior parietal (18% lower on the right, and 12% lower on the left) regions. Statistical
parametric mapping (SPM) analyses showed similar results: ε4 carriers had lower
metabolism in inferior parietal and posterior cingulate and left lateral temporal areas. The
results were similar even when the two ε4 homozygotes were removed from the analyses.
Baseline glucose metabolic rates in several ROIs predicted 2-year memory decline in ε4
carriers. In repeat PET scans that were obtained for 10 ε4 carriers and 10 non-ε4 carriers
after 2 years, a significant metabolic decline was noted for ε4 carriers (but not for non-ε4
carriers) in posterior cingulate (4%; ROI analyses) and in inferior parietal and lateral
temporal cortices (5%; SPM analyses). Non-ε4 carriers showed metabolic decline, primarily
in the frontal cortex, consistent with normal aging.
As part of a study of cognitively normal late middle-aged subjects with family history of
probable AD, FDG-PET was done in 11 ε4 homozygotes and 22 control subjects without the
ε4 allele who were matched for gender, age, education, and level of cognitive performance
[16]. The ε4 homozygotes had significantly reduced rates of glucose metabolism in the same
posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied
patients with probable AD. They also had reduced rates of glucose metabolism in additional
prefrontal regions, which may be preferentially affected during normal aging.
The same investigators observed similar results with a larger dataset of 160 cognitively
normal late middle-aged subjects who had a first-degree relative with AD (36 ε4
homozygotes, 46 heterozygotes, and 78 ε4 non-carriers who were individually matched for
their gender, age, educational level, and cognitive performance) ε4 gene dose was correlated
with lower FDG-PET-assessed cerebral glucose metabolism in regions of the precuneus and
the posterior cingulate, parietotemporal, and frontal cortices [17•].
In another report from the same group, longitudinal PET cerebral glucose metabolic data
after 2 years were available for 10 cognitively normal ε4 heterozygotes and 15 non-carriers
50 to 63 years of age, with a reported family history of AD [35]. The ε4 heterozygotes had
significant cerebral metabolism declines in the vicinity of temporal, posterior cingulate, and
prefrontal cortex, basal forebrain, parahippocampal gyrus, and thalamus, and these declines
were significantly greater than those noted for the ε4 noncarriers.
A 3-year FDG-PET longitudinal study of 48 healthy normal elderly (12 of whom showed
cognitive decline, 11 to MCI, and one to AD) included eight ε4 carriers and 17 noncarriers
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[18]. ε4 carriers showed lower lateral temporal lobe and superior temporal gyrus
metabolism. Among subjects who showed cognitive decline, ε4 carriers (but not ε4
noncarriers) showed lower baseline lateral temporal lobe metabolism and more prominent
lateral temporal lobe reductions over time (13% for ε4 carriers vs 3% for noncarriers).
Young subjects
Association between APOE genotype and functional brain imaging changes has been
addressed by only two studies. In one, FDG-PET scans were obtained for normal volunteers
20 to 39 years of age (12 ε4/ε3 and 15 ε4 noncarriers) individually matched for gender, age,
educational level, and cognitive performance [19••]. Similar to previously studied patients
with probable AD and late middle-aged ε4 carriers, the young ε4 carriers had abnormally
low rates of glucose metabolism bilaterally in the posterior cingulate, parietal, temporal, and
prefrontal cortex.
Our group used H215O PET to measure cerebral blood flow for younger college-age
subjects (three ε4 carriers and 15 noncarriers) [20•]. The groups were of similar age (26 vs
23 years), gender, education, and neuropsychologic performance. ε4 carriers showed
significantly lower cerebral blood flow in the left and right inferior temporal gyri. However,
ε4 carriers also had higher flow in the left insula, right supramarginal gyrus, and the inferior
occipital gyrus.
Functional Imaging During Cerebral Activation
Middle-aged and elderly subjects
One study used functional MRI (fMRI) during visual naming and letter fluency tasks in 26
middle-aged, cognitively normal women who were classified as high risk (ε4 carriers with at
least one first-degree relative with AD) and low risk (neither of the above). High-risk
women showed decreased fMRI activation in bilateral mid and posterior inferotemporal
regions during naming and fluency tasks despite identical performance [22].
In a follow-up study from the same group of investigators, with 38 middle-aged women
participants, the high-risk group showed significantly decreased activation at left posterior
fusiform and bilateral anterolateral occipital areas [23]. However, increased activation in the
left parietal regions (mostly extent and less so magnitude) also was noted for the ε4 carriers.
In a small pilot study of nondemented elderly subjects, three ε4 carriers and three
noncarriers had fMRI during learning and recall of a face-naming task [26]. ε4 carriers
seemed to have increased activation in dorsolateral prefrontal cortex during the easy version
of the task, but were unable to further increase the activation during the more demanding
version of the task.
In another study of cognitively intact elderly subjects, 13 ε4 carriers (12 ε4 heterozygotes)
and 12 non-ε4-carriers had fMRI during performance of a verbal working memory task [21].
No APOE-related differences were detected for various levels of task difficulty. The authors
concluded that the effect of APOE was specific to memory and not related to general task
difficulty.
The same group of investigators used fMRI during performance of a verbal memory task for
16 elderly ε4 carriers (14 heterozygotes) and 14 elderly ε3 homozygotes who were
cognitively normal [27•]. The magnitude and the extent of fMRI activation were greater
among ε4 carriers in the left prefrontal and bilateral orbitofrontal, superior temporal, and
inferior and superior parietal regions. During recall, the average increase in signal intensity
was nearly twice as great among ε4 carriers as compared with ε4 noncarriers. The results
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were interpreted as evidence of compensatory processing in subjects at risk for AD; that is,
the APOE ε4 subjects use additional cognitive resources to bring their performance to a
normal level.
In a more recent study of nondemented elderly, 10 ε4 carriers and 10 ε4 noncarriers had
fMRI during a picture learning task [24]. In SPM analyses, ε4 carriers showed significantly
greater activations during novel picture encoding in bilateral fusiform gyrus, right superior
parietal lobule, left cerebellum, left middle frontal gyrus, and medial frontal gyrus. In ROI
analyses, ε4 carriers had greater fMRI responses in left inferior frontal, bilateral fusiform,
and right hippocampal and parahippocampal cortices. However, there also were areas within
the left hippocampal and parahippocampal cortex where ε4 carriers showed smaller
activations.
In another study, fMRI was used to record cerebral activation during performance of a face-
name associative encoding task in a mixture of 10 cognitively intact elderly subjects, nine
subjects with MCI, and 10 subjects with probable AD [28]. As compared to the 16 non-ε4
carriers, the 13 ε4 carriers showed a greater extent of entorhinal cortex activation.
Our group used H215O PET for imaging of 26 non-ε4 carriers and six elderly ε4 carriers
while they did a serial recognition nonverbal memory task with titrated task difficulty so that
recognition accuracy was similar for all subjects [25•]. As compared with non-ε4 carriers, ε4
carriers showed significantly decreased activation in left precuneus, left superior temporal,
right superior frontal, left postcentral, and posterior cingulate gyri. Because recognition
accuracy was titrated, the differences in activation were considered not to reflect task
difficulty, but to indicate memory-related altered cognitive processing for different APOE
genotypes.
Young subjects
To our knowledge, there is only one study that has investigated APOE-related differences
during functional activation in this age group. Using H215O PET, we did scans of 20
healthy young adults (age, 19 to 28 years; four ε4 carriers and 16 non-ε4 carriers) while they
did a nonverbal memory task [29••]. In comparison to subjects without the ε4 allele, ε4
carriers showed significantly lower activation in right superior temporal and left fusiform
gyri and significantly higher activation in left middle temporal and right transverse temporal
gyri. These results suggest that APOE-dependent modulation of cerebral flow during
cognitive activation may be present even at a very young age.
Discussion
Many studies have investigated APOE-related differences in cerebral structure, blood flow,
metabolism, and activation in an attempt to detect early changes in subjects at risk for AD.
Structural MRI studies have produced conflicting results. Three structural imaging studies
have failed to detect APOE-related differences [6–8], whereas five studies seem to suggest
that ε4 carriers have more pronounced atrophy [9,10,11•,12,13]. This seems to be the case in
particular for medial temporal structures (which are the areas that usually are investigated).
The effect seems to be more prominent on the right hippocampus according to one study
[10]. According to another, the association between ε4 allele and increased hippocampal
atrophy is stronger in women [12]. Faster hippocampal volume loss has been shown for
nondemented ε4 carriers by one study [8].
The associations are more consistent when it comes to functional imaging during rest. All
five studies in middle-aged and elderly subjects have found decreased cerebral metabolism
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for ε4 carriers [14–16,17•,18]. Decreases in metabolism have been noted mostly in areas that
usually are affected by AD. Additionally, two studies have found that ε4 carriers also show
faster cerebral metabolic reductions over time [18,35]. For young subjects, one study found
decreased cerebral metabolism [19••], and another found decreased perfusion [20•] in areas
affected by AD at older ages. Nevertheless, the latter study also reported brain regions of
increased perfusion for young ε4 carriers [20•]. Therefore, carriers of the ε4 allele seem to
have resting metabolism and flow changes in young adulthood, several decades before the
possible onset of dementia.
It has been hypothesized that imaging during performance of cognitive tasks may be more
sensitive in revealing earlier and subtler changes in cognitive function in subjects at risk for
AD, such as ε4 carriers. However, activation imaging studies in middle-aged and elderly
subjects have produced variable results. One study found no APOE-related activation
differences during performance of a verbal working memory task [21]. Four studies have
reported that there are brain regions in which ε4 carriers show decreased activation during
cognitive task performance [22–24,25•]. Five studies have found increased activation in
various brain regions for ε4 carriers [23,24,26,27•,28]. Increased activations often have been
interpreted as evidence of compensatory processing in subjects at risk for AD; that is, APOE
ε4 subjects use additional cognitive resources to bring their performance to a normal level.
The single existing study in young subjects has reported areas with increased activation and
other areas with decreased activation for ε4 carriers during performance of a nonverbal
memory task [29••], suggesting that APOE-dependent modulation of cerebral flow during
performance of cognitive tasks may be present even at a very young age.
Overall, many of the imaging studies conclude that in carriers of the ε4 allele, a common
AD susceptibility polymorphism that identifies genetically at-risk individuals, subtle
changes in cerebral structure of function occur long before the onset of clinical
manifestations of disease. Therefore, many authors raise the possibility of using imaging as
a quantitative presymptomatic endophenotype to help evaluate the individual and aggregate
effects of putative genetic and nongenetic modifiers of AD risk. Assuming that structural
and metabolic declines are related to predisposition for AD, some authors advocate possible
use of imaging as a therapeutic response monitor (ie, a surrogate endpoint for testing the
potential of experimental treatments to prevent the disorder) without having to study
thousands of research subjects or wait many years to determine whether or when treated
individuals develop symptoms.
Possible reasons for study discrepancies
Decreased power cannot fully explain why some structural MRI studies have failed to detect
more prominent atrophy for middle-aged and elderly ε4 carriers because some of them have
included a large number of participants [6,7,34], whereas APOE-related associations with
atrophy have been detected by considerably smaller studies [10,13]. Various methodological
differences may account for the differences among studies. Examples include differences in
subject selection, differences in levels of cognitive performance, different age groups, etc.
All of these may affect relative percentages of subjects harboring subclinical AD-type
pathologic changes in each study, and therefore different degrees of underlying MRI brain
atrophy. Differences in cerebral activation studies can be accounted for by various other
additional factors: different imaging modalities (FDG assessing brain metabolism versus
H215O assessing blood flow), different methods of analysis (ROI versus SPM voxel-wise),
different applied statistical thresholds, differences in power (more spatially restricted
activations in some studies may be the result of a limited number of participants), etc. The
relative proportions of homozygotes and heterozygotes in different studies also may have an
important impact on power. Presence of parametric changes in activation with increasing
Scarmeas and Stern Page 6













number of ε4 alleles would provide a much more convincing association between the APOE
genotype and cerebral activation.
More importantly, it is not surprising that activation task differences may result in
activations and deactivations of variable brain regions. First, there are differences in
underlying cognitive functions being tested (ie, naming, fluency [22,23], face naming
[26,28], verbal working memory [21], verbal episodic memory [27•], nonverbal memory
[25•], picture learning [24]). Second, there are differences regarding acquisition of scanning
data during different phases of cognitive tasks (ie, encoding and retrieval [21,25•], or
learning and recall separately [27•]). Third, variable experimental designs have been used.
Although most studies have used varying degrees of task difficulty, some studies have used
equated task difficulty so that recognition accuracy was similar for each participant [20•,
25•], or have compared subjects at various levels of task difficulty [21]. Several functional
imaging studies suggest that a common response to increasing task difficulty in normal
individuals is increased activation of areas involved in an easier version of the task and/or
the recruitment of additional brain areas [36,37]. Therefore, areas reportedly associated with
APOE-related compensatory activation that have been identified in experiments with
uncontrolled task difficulty may reflect modulation of the same networks in response to
differential difficulty (ie, increased task-related effort rather than APOE-related
compensatory recruitment).
Biopathological and functional considerations
Effects of the APOE genotype on lipid metabolism [38], blood pressure [39], atherosclerosis
[40], ischemic heart disease [41], myocardial infarction [42], and cognitive performance in
type I diabetes [43] have been documented in very young subjects and in children [44,45].
Animal studies have indicated that the APOE genotype seems to affect stress response and
spatial memory [46] and regulates synaptic plasticity and long-term potentiation in the
hippocampus [47] of young mice. Therefore, it is conceivable that APOE-related alterations
in cerebral physiology may exist from a very young age.
There are known early biochemical changes in neuronal processes and synapses (which may
be manifested in cerebral blood flow activation studies) long before structural pathology is
detected [48]. It is also known that symptoms of AD are preceded by a period of unknown
duration during which neuropathologic alterations accumulate in the brain without
associated memory loss or other detectable cognitive change. The increased risk for AD in
subjects carrying the ε4 allele has been thought to be mediated by the APOE genotype being
implicated in β amyloid and/or neurofibrillary tangle [49,50] biochemical pathways. In a
neuropathological study of 105 autopsy cases who showed no signs of dementia, abnormally
high brain β amyloid levels (the deposition of which is the hallmark of AD) were reported
for ε4 carriers as young as 40 years [51]. That study concluded that the ε4 allele predisposes
the carriers to begin accumulating β amyloid earlier in life than noncarriers. In another
study, the ε4 allele was associated with presence of neurofibrillary tangle changes in 44
autopsy cases of young subjects (mean age, 38 years old; range, 22 to 46 years) [52]. After
AD onset, patients with AD with the ε4 allele have been reported to carry increased β
amyloid burden [1,50]. The ε4 allele also has been associated with more profound deficits in
cholinergic neurons [53,54]. Therefore, brain regions in which APOE-related significant
differences have been detected in structural or functional imaging studies may have already
been affected by AD pathology in subjects at risk for AD (the absence of clinical dementia
may be the result of unaffected brain regions providing enough redundancy for normal
cognitive performance).
Increased and decreased activations for the ε4 carriers have been observed in imaging
studies during cognitive tasks. Overall, the interpretation of increased or decreased
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activation has been very controversial. There have been activation imaging studies in
healthy subjects [37,55–57] but also in AD patients [58] in whom decreased activation
reflected more efficient processing, whereas increased activation was associated with less
effective cognitive strategies. Therefore, it is not clear how AD pathology relates to the
APOE-dependent activation differences. Areas with differential activation in the ε4 carriers
may reflect malfunctioning (taking the form of either overactivation or deactivation) because
of more severe AD pathological involvement for ε4 carriers in these regions. Alternatively,
some of these regions may still be spared by AD pathology and are recruited for task
performance by ε4 carriers because of more severe pathologic involvement in other regions.
However, several other considerations make the possibility of indolent AD pathology
causing APOE-related differences less plausible. That the APOE-related differences in
resting flow and activation are detected at such a young age (four to five decades before the
possible onset of dementia) weakens the hypothesized link with AD. The presence of the ε4
allele is not equivalent to early AD: a significant proportion of ε4 heterozygotes will never
develop AD. It has been proposed that ε4 facilitates rather than causes AD [59], and ε4 has
been implicated in impaired brain repair mechanisms that may place subjects at risk for AD
or other brain diseases. Important direct effects of the ε4 allele on the nervous system
include impaired neuroregeneration within the dentate gyrus [60] and increased vulnerability
to exogenous neurotoxins [61]. Therefore, the observed imaging patterns of ε4 carriers may
be the early signature of an APOE-dependent alteration in brain physiology, which may
result in greater vulnerability to environmental effects (such as traumatic brain injury or
other insult) later in life. Subsequently, the detected activation differences may reflect an
APOE-dependant physiologic heterogeneity (ie, different structure or different resting flow-
metabolism or different utilization of brain regions during task performance), which may not
necessarily lead to disease.
Conclusions
Overall, subjects with a genetic risk for AD (ε4 allele carriers) have alterations in brain
structure and function, even at a point in time when behavioral, cognitive, or clinical
evidence of disease is absent. These alterations may be markers of early AD or they may just
reflect an APOE-related cerebral physiologic heterogeneity. There exists significant
variability of scientific findings, which may be related to underlying methodological
differences among imaging studies. Nevertheless, imaging may be a more sensitive tool than
behavioral-cognitive tests for measuring early cerebral structure-function or reorganization
in response to possible incipient pathological processes.
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